November 9, 2018 / 4:30 PM / 9 days ago

BRIEF-Zhejiang Huahai Pharmaceutical Clarifies Reports Related To Sandoz's Product Recall

Nov 10 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd :

* SAYS IT CLARIFIES ONLINE REPORTS ON HUAHAI BEING INVOLVED IN MANUFACTURING RAW MATERIALS CONTAINING NDEA IMPURITIES THAT PROMPTED SANDOZ TO RECALL A BATCH OF ITS LOSARTAN POTASSIUM HYDROCHLOROTHIAZIDE TABLETS

* SAYS THE REPORTS WERE VAGUE AND DID NOT CLEARLY STATE THE FACTS,WHICH HAS MISLED INVESTORS Source text in Chinese: bit.ly/2qBM7M3 Further company coverage: (Reporting by Hong Kong newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below